v3.26.1
Revenue - Narrative (Details)
$ in Thousands
12 Months Ended
Jun. 22, 2021
USD ($)
Dec. 31, 2025
USD ($)
financialInstrument
performanceObligation
Dec. 31, 2024
USD ($)
Disaggregation of Revenue [Line Items]      
Accounts receivable, net   $ 24,024 $ 15
Accounts receivable, net (less than)     100
Revenue   $ 75,388 10,120
Number of freestanding financial instruments | financialInstrument   1  
Number of combined performance obligation | performanceObligation   1  
License      
Disaggregation of Revenue [Line Items]      
Revenue   $ 1,070 10,120
License | ModernaTX, Inc      
Disaggregation of Revenue [Line Items]      
Liabilities related to future royalties and milestones, net - non-current $ 1,500    
Commercial license payment of commercial option fee $ 2,000    
Clinical milestone achieved, amount   1,000  
License | BioNTech      
Disaggregation of Revenue [Line Items]      
Revenue   0 10,100
License and Options | BioNTech      
Disaggregation of Revenue [Line Items]      
Remaining performance obligation, variable consideration amount   32,000  
Technology Options | BioNTech      
Disaggregation of Revenue [Line Items]      
Revenue   10,000  
Royalty      
Disaggregation of Revenue [Line Items]      
Revenue   $ 0 $ 0